This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study
by Zacks Equity Research
Conatus' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on compensated NASH cirrhosis patients at high risk of decompensation.
Roche's Kadcyla Halves Death Risk in Breast Cancer Study
by Zacks Equity Research
Roche (RHHBY) announces detailed data from a late-stage study on Kadcyla in early breast cancer patients. Kadcyla reduces risk of disease recurrence by 50% compared to Herceptin.
Roche's Tecentriq Combination Gets Priority Review by FDA
by Zacks Equity Research
The FDA accepts and grants Priority Review to Roche's (RHHBY) sBLA for Tecentriq in combination with carboplatin and etoposide for the initial treatment of patients withextensive-stage small cell lung cancer.
Incyte (INCY) Announces Positive Data on Jakafi for GVHD
by Zacks Equity Research
Incyte (INCY) announces positive data on lead drug Jakafi at the ASH meet for the indication of acute GVHD.
Gilead (GILD) Announces Data on CAR T Therapy Candidate
by Zacks Equity Research
Gilead (GILD) announces data on chimeric antigen receptor T (CAR T) cell therapy candidate at the ASH for the treatment of patients with relapsed or refractory acute lymphoblastic leukemia.
FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101
by Zacks Equity Research
The FDA accepts Novartis' (NVS) BLA for AVXS-101 and grants Priority Review to the same.
Global Blood Therapeutics' Voxelotor on Faster Approval Path
by Zacks Equity Research
Global Blood Therapeutics (GBT) announces FDA nod for an accelerated approval pathway for voxelotor as a treatment for sickle cell disease. Stock rallies.
Glaxo to Sell India's Popular Horlicks Brand to Unilever
by Zacks Equity Research
Glaxo (GSK) divests its Horlicks and other nutrition products in India to Unilever.
Novartis' Gilenya Approved in EU for Expanded Population
by Zacks Equity Research
Novartis (NVS) gains the EU approval for MS drug Gilenya for children who are 10-17 years old with relapsing-remitting forms of multiple sclerosis.
Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma
by Zacks Equity Research
Teva (TEVA) and partner Celltrion get FDA nod for approval of their biosimilar to Roche's Rituxan in three Non-Hodgkin's lymphoma indications.
Roche (RHHBY) to Acquire Jecure and Enter the NASH Space
by Zacks Equity Research
Roche (RHHBY) is all set to acquire biotech Jecure Therapeutics, which focuses on the discovery of novel therapeutics for the treatment of NASH and liver fibrosis.
4 Big Pharma Stocks to Add to Your Portfolio in December
by Kinjel Shah
The large-cap pharma industry has been on a strong footing lately. Here are four stocks from the space that investors may consider betting on.
Novartis (NVS) Receives EC Approval for Neulasta Biosimilar
by Zacks Equity Research
Novartis (NVS) obtains EC approval for Ziextenzo, the biosimilar of Amgen's Neulasta.
Celgene & Bluebird's CAR T Therapy Study Completes Enrollment
by Zacks Equity Research
Celgene (CELG) and partner bluebird complete enrollment in a phase II study for CAR T cell therapy candidate, bb2121 for patients with relapsed and refractory multiple myeloma.
Glaxo's Horlicks Sale Bid Heats Up, Nestle, Unilever Close In
by Zacks Equity Research
Per a Financial Times report, Glaxo (GSK) is in exclusive talks with Unilever to sell its Horlicks brand in India. Another report in an India-based newspaper says Nestle is close to buying Horlicks.
3 Reasons Why Glaxo (GSK) Stock is Up This Year So Far
by Zacks Equity Research
Glaxo's (GSK) shares have outperformed the industry this year. Here are some reasons for the same.
Spark Therapeutics' Luxturna Gets EU Approval for Vision Loss
by Zacks Equity Research
Spark Therapeutics (ONCE) announces approval in Europe for its gene therapy, Luxturna, for treating inherited retinal dystrophy with RPE65 mutation. Novartis will develop and distribute it in Europe.
4 Reasons Why Lilly is Up More Than 30% This Year So Far
by Zacks Equity Research
Eli Lilly's (LLY) stock is up 33.7% this year so far. Let us have a look at the reasons for the same.
Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs
by Zacks Equity Research
FDA grants approval to Pfizer's (PFE) new cancer drug and label expansion of AbbVie/Roche's Venclexta. CHMP gives nod to several drugs
Novartis Gets Approval for Gene Therapy Luxturna in Europe
by Zacks Equity Research
Novartis (NVS) obtains EC approval for a one-time gene therapy, Luxturna for the treatment of patients with vision loss due to a genetic mutation in both copies of the RPE65gene.
Roche, AbbVie Get FDA Approval for Venclexta Label Expansion
by Zacks Equity Research
Roche (RHHBY) gets accelerated approval for Venclexta for the treatment of patients suffering from newly-diagnosed AML who are aged 75 years or older.
Gilead's Vemlidy Gets Approval in China for HBV Infection
by Zacks Equity Research
Gilead (GILD) obtains approval for Vemlidy in China for the treatment of chronic hepatitis B in adults and adolescents.
Novartis (NVS) Gets FDA Nod for Label Expansion of Promacta
by Zacks Equity Research
Novartis (NVS) obtains FDA approval for the label expansion of Promacta. The CHMP also issues a positive opinion for the label expansion of Kisqali.
Drug Pricing Resurfaces, Pfizer to Raise Cost of 41 Drugs
by Zacks Equity Research
Per a Wall Street report, Pfizer (PFE) plans to increase the list prices of its 41 prescription drugs in 2019.
The Zacks Analyst Blog Highlights: Chevron, Novartis, Qualcomm, TJX and Deere
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chevron, Novartis, Qualcomm, TJX and Deere